In eukaryotes, U1 small nuclear ribonucleoprotein (snRNP) forms spliceosomes in equal stoichiometry with U2, U4, U5 and U6 snRNPs; however, its abundance in human far exceeds that of the other snRNPs. Here we used antisense morpholino oligonucleotide to U1 snRNA to achieve functional U1 snRNP knockdown in HeLa cells, and identified accumulated unspliced pre-mRNAs by genomic tiling microarrays. In addition to inhibiting splicing, U1 snRNP knockdown caused premature cleavage and polyadenylation in numerous pre-mRNAs at cryptic polyadenylation signals, frequently in introns near (,5 kilobases) the start of the transcript. This did not occur when splicing was inhibited with U2 snRNA antisense morpholino oligonucleotide or the U2-snRNP-inactivating drug spliceostatin A unless U1 antisense morpholino oligonucleotide was also included. We further show that U1 snRNA-pre-mRNA base pairing was required to suppress premature cleavage and polyadenylation from nearby cryptic polyadenylation signals located in introns. These findings reveal a critical splicing-independent function for U1 snRNP in protecting the transcriptome, which we propose explains its overabundance.
In eukaryotes, U1 small nuclear ribonucleoprotein (snRNP) forms spliceosomes in equal stoichiometry with U2, U4, U5 and U6 snRNPs; however, its abundance in human far exceeds that of the other snRNPs. Here we used antisense morpholino oligonucleotide to U1 snRNA to achieve functional U1 snRNP knockdown in HeLa cells, and identified accumulated unspliced pre-mRNAs by genomic tiling microarrays. In addition to inhibiting splicing, U1 snRNP knockdown caused premature cleavage and polyadenylation in numerous pre-mRNAs at cryptic polyadenylation signals, frequently in introns near (,5 kilobases) the start of the transcript. This did not occur when splicing was inhibited with U2 snRNA antisense morpholino oligonucleotide or the U2-snRNP-inactivating drug spliceostatin A unless U1 antisense morpholino oligonucleotide was also included. We further show that U1 snRNA-pre-mRNA base pairing was required to suppress premature cleavage and polyadenylation from nearby cryptic polyadenylation signals located in introns. These findings reveal a critical splicing-independent function for U1 snRNP in protecting the transcriptome, which we propose explains its overabundance.
Messenger RNAs in eukaryotic cells are produced from primary transcripts (pre-mRNAs) by extensive post-transcriptional processing, including 59 end capping, removal of introns by splicing, and 39 end cleavage and polyadenylation [1] [2] [3] [4] . Each splicing reaction is carried out by a spliceosome, a large RNA-protein complex comprised predominantly of snRNPs [5] [6] [7] [8] . The U1, U2, U4, U6 and U5 snRNPs are components of the major (U2-type) spliceosome, whereas a much less abundant (,1%) minor (U12-type) spliceosome is comprised of U11, U12, U4atac, U6atac and U5 snRNPs 5, [9] [10] [11] . The snRNPs, aided by specific RNA-binding proteins, recognize by snRNA-pre-mRNA base pairing, canonical sequences within pre-mRNAs that define the major-and minor-class introns, including the intron-exon junctions at the 59-and 39-splice sites. U1 snRNP has an essential role in defining the 59 splice site by RNA-RNA base pairing via the 59 nine nucleotide sequence of U1 snRNA. To form the catalytic core of the spliceosome, the snRNPs come together in 1:1 stoichiometry as a modular machine 5 . However, the abundance of the various snRNPs in cells does not reflect their equimolarity in the spliceosomes. This is particularly striking for U1 snRNP which, at an estimated copy number of ,10 6 molecules per human cell (HeLa), is much more abundant than the other snRNPs in higher eukaryotes 12 . The potential role of the different amounts of the snRNPs is not known.
Our interest in exploring a potential function for cellular snRNP abundance arose from earlier observations that deficiency in the survival of motor neurons (SMN) protein, a key component in snRNP biogenesis [13] [14] [15] [16] [17] , perturbs the normal abundance of snRNPs in cells (the snRNP repertoire) 18, 19 and causes widespread splicing abnormalities 19 . The possible effect of snRNP abundance changes on splicing and the molecular consequences of SMN deficiency in general are of importance because SMN deficiency is the cause of spinal muscular atrophy, an often fatal motor neuron degenerative disease [20] [21] [22] . However, the snRNP repertoire changes that occur in an SMN-deficient spinal muscular atrophy mouse model vary in different tissues and are not uniform for all of the snRNPs 18, 19 , including both downregulation and upregulation in the levels of several snRNPs simultaneously, making them difficult to recapitulate. To circumvent this, we investigated the effect of functional reduction of individual snRNPs on the transcriptome using antisense morpholino oligonucleotide (AMO). Our experiments revealed an unexpected function for U1 snRNP in protecting pre-mRNAs from premature cleavage and polyadenylation (PCPA), distinct from its role in splicing.
Functional knockdown of U1 snRNP with AMO
To decrease the amount of functional U1 snRNP, we designed an AMO that covers the 59 end of U1 snRNA (U1 AMO) to block its binding to 59 splice sites. To confirm the binding of U1 AMO to U1 snRNP and determine the amount required to inhibit it in cells, we performed an RNase H protection assay. Extracts from cells transfected with a scrambled control AMO 23, 24 or various concentrations of U1 AMO were incubated with RNase H and an antisense DNA oligonucleotide probe also complementary to U1 snRNA's 59 end sequence ( Fig. 1a) . A dose-dependent decrease in the amount of cleaved U1 snRNA was observed as the amount of transfected U1 AMO was increased ( Fig. 1a) , indicating that the U1 AMO prevented the antisense DNA oligonucleotide probe from binding and eliciting RNase H digestion. Complete or near-complete interference with U1 snRNA 59 base pairing in cells was observed with 7.5 mM of U1 AMO (Fig. 1a ). In addition, we used in situ hybridization with a LNA probe complementary to U1 snRNA's 59 sequence (nucleotides 1-25) to determine if the U1 AMO was bound to the same sequence in cells. The images ( Fig. 1b ) demonstrate that the U1 AMO indeed shields U1 snRNA's 59 sequence in a dose-dependent manner and that this sequence is completely inaccessible at 7.5 mM U1 AMO, the concentration that was used in all subsequent U1 AMO transfection experiments. To confirm that the U1 AMO inhibited the activity of U1 snRNP directly, we tested its effect on the in vitro splicing. As shown in Fig. 1c , U1 AMO, but not control AMO, strongly decreased the amount of spliced product for Ad2DIVS. Thus, U1 AMO functionally inactivated U1 snRNP both in vivo and in vitro.
Unspliced pre-mRNA accumulation after splicing inhibition
To obtain a high-resolution global picture of the transcriptome changes that occurred upon U1 snRNP knockdown, including effects on introns and exons, we analysed total RNA prepared from HeLa cells transfected with either U1 or control AMOs using Affymetrix GeneChip Human Tiling 2.0R E arrays. This high-density genomic tiling array includes tiled probes (25-mer oligonucleotides spaced at 10 nucleotides) covering the entire genomic sequence of chromosomes 5, 7 and 16, which are estimated to contain ,3,600 genes. All experiments were carried out as separate biological triplicates and treatments were for 8 h to allow transfected cells to recover and for sufficient signals to accumulate above background. As a reference, we treated cells in parallel with the potent and general splicing inhibitor spliceostatin A (SSA), which targets the splicing factor SF3b, a component of U2 snRNP 25 . As the amount of each pre-mRNA is typically very small and difficult to detect, large increases in intron signals provided the most definitive evidence for the accumulation of unspliced pre-mRNAs, ensuring that the corresponding sequences were actively transcribed and their unspliced transcripts are sufficiently stable to be scored. Statistical analysis was performed to identify significant changes that exceeded the following thresholds: fold-change $2, P-value ,0.01 and length of affected region $100 nucleotides (corresponding to three or more consecutive probes). This identified 319 genes that showed accumulation typically of one or more introns in either U1-AMO-transfected (211 genes) or SSAtreated (216 genes) cells. From the outset we expected two patterns due to splicing inhibition. A general reduction in all signals from a transcript could reflect that unspliced pre-mRNA is less stable and rapidly degraded; however, we did not include them in our analysis as they could also potentially result from transcriptional downregulation. We also expected that U1 AMO and SSA would show similar patterns of intron accumulation throughout the transcript as a result of splicing inhibition in general, but this was observed for only 98 genes (30.7%), as exemplified by ETF1 ( Fig. 2 ). A small number of genes (41 genes; 12.9%) showed other profiles but did not exhibit any coherent pattern. Unexpectedly, however, most genes (180 genes; 56.4%) showed different patterns for U1 AMO and SSA (HSPA9, SRRM2 and CBFB in Fig. 2 ).
U1 snRNP knockdown causes PCPA
Most notably, the majority of the affected genes in the U1-AMOtransfected cells showed a similar pattern consisting of strong intron signals that terminated prematurely relative to SSA, for example in HSPA9, SRRM2 and CBFB as indicated by arrows in Fig. 2 . This usually occurred in introns in the first quarter of the gene with a strong 59 bias, as shown for several functionally diverse genes in Fig. 3 . Notably, in U1-AMO-transfected cells there was an abrupt decrease in unspliced intron signals frequently within 3-5 kb from the start of the transcript. From the point at which a sharp drop in the signals in U1-AMO-treated cells was observed, all downstream signals, including exons, were consistently lower than those of control and the SSA-treated samples. To define the termination point, we characterized cDNA fragments from this region (indicated by arrows in Fig. 3 ), including 39 rapid amplification of cDNA ends (RACE) products for transcripts of several genes that showed this pattern from U1-AMO-transfected cells, of which NR3C1 and STK17A were sequenced ( Fig. 4a) . Surprisingly, this revealed that the transcripts had a poly(A) sequence at the 39 end that is not found in the genomic sequence and which was added post-transcriptionally ,20 nucleotides downstream of a potential polyadenylation signal (PAS), typically AAUAAA (Fig. 4a ). These findings indicate that pre-mRNAs are prematurely cleaved and polyadenylated within an intron when the levels of functional U1 snRNP are reduced.
To determine if these putative PASs are functionally relevant, we constructed a NR3C1 mini-gene comprising exons 2 and 3 which flank a truncated intron 2 where the cleavage and polyadenylation occurred. An identical plasmid was also constructed with a mutation in the putative PAS in intron 2 inferred from the tiling array results (Fig. 4b ). Cells expressing each of these plasmids were then transfected with either control or U1 AMOs. Wild-type plasmid-expressing cells showed PCPA at the cryptic PAS only after U1 AMO treatment (Fig. 4b) , consistent with the result of the endogenous NR3C1 gene. No cleavage and polyadenylation occurred in the transcript containing a mutant PAS in either control or U1-AMO-transfected ARTICLE RESEARCH cells (Fig. 4b) , demonstrating that this cryptic PAS is functional and that this process is similar to that which occurs normally at the 39 ends of mRNAs.
PCPA suppression is a non-splicing function of U1 snRNP
Unlike U1 AMO, tiling arrays with SSA or U2 AMO (which generally showed a tiling array pattern of splicing inhibition similar to that of SSA; Supplementary Fig. 1 ) did not show PCPA. To test this directly, we used an oligo(dT) reverse primer to amplify NR3C1 and STK17A transcripts in control, U1 or U2-AMO-treated cells and SSA-treated cells (Fig. 5a ). As expected, PCPA was observed for U1 AMO; however, none or very little was seen in U2-AMO-and SSA-treated cells, which could be due to destabilization of U1 snRNP binding upon U2 snRNP inhibition. Notably, PCPA still occurred in cells treated simultaneously with U1 AMO and SSA, indicating that the effect of U1 inhibition is dominant over splicing inhibition (Fig. 5b ). We conclude that U1 suppresses cleavage and polyadenylation and that this is not a consequence of the splicing inhibition that it causes, as neither U2 AMO nor SSA showed this effect. The functional PAS from which cleavage and polyadenylation occurred in the NR3C1 mini-gene upon U1 snRNP depletion is less than 400 nucleotides downstream of the 59 splice site and it thus seemed likely that U1 snRNP that is base paired to this 59 splice site suppresses utilization of this cryptic PAS. To test this, we mutated the 59 splice site, which inactivated splicing as evidenced by the lack of mRNA (Fig. 5c ). Whereas the wild-type mini-gene showed PCPA only upon U1 AMO treatment, in 59 splice site mutant transfected cells, PCPA was observed even with control morpholino treatment. This indicates that U1 snRNP that is base paired to the 59 splice site is able to suppress the cryptic PAS (Fig. 5c ). However, treatment of the 59 splice site mutant with U1 AMO resulted in ,4-fold increase in PCPA from the same cryptic PAS and concomitantly ,8-fold decrease in polyadenylation from the normal PAS at the transcript's 39 end (Fig. 5c, d) . Therefore, U1 snRNP that is base paired to sequences other than the 59 splice site also suppresses PCPA. The large number of potential U1 snRNP binding sites in introns precluded identification of other sites from which U1 snRNP might suppress premature utilization of this PAS ( Supplementary Fig. 2) . These findings indicate that the PCPA results from loss of the base pairing of the 59 end of U1 snRNA with the pre-mRNA, indicating a T  T  TT  T  T  T  T  T  T  T  T  T  T T  T  C  T  T  G  T  T  TT  T  T  T  T  T  T  T  T  T  T  G  G G cryptic PASs in introns. a, 39 RACE using nested PCR was performed to detect polyadenylated mRNAs using total RNA from U1-AMO-transfected cells (7.5 mM, 8 h). Sequencing results of the 39 RACE products for the NR3C1 and STK17A genes are shown with the corresponding genomic sequence in black. The poly(A) tails are shaded and the putative PASs are indicated in red-bordered boxes. b, HeLa cells were transfected with the wild-type and PAS mutant (mutated from AAUAAA to GAAUUC) NR3C1 mini-gene construct followed by either control or U1 AMOs. 39 RACE was performed as described in a. The mini-gene structure is depicted above the gel, with a blue arrow indicating the forward primer for 39 RACE. Grey arrowhead, PAS mutation; PCPA, premature cleavage and polyadenylation. Band sizes (bp) are indicated to the left of the gel.
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U1 snRNP function other than and independent of its known function in splicing.
Discussion
Our experiments here revealed an unexpected function for U1 snRNP in protecting transcripts from PCPA in addition to and independent of its role in splicing. As a reference for U1 AMO, the general splicing inhibitor SSA 25 , which inactivates the U2 snRNP component SF3b (refs 5, 26) , allowed identification of introns that were stable enough and that accumulate to significantly detectable levels when their splicing was inhibited. As expected, the patterns observed for U1 AMO and SSA (which is similar to that of U2 AMO) showed that both efficiently inhibited splicing. However, U1 snRNP functional reduction had an additional and marked effect, resulting in the failure to produce full-length pre-mRNA from the majority of genes in our data set. We showed that this was due to premature cleavage and polyadenylation from a cryptic PAS, typically in an intron and frequently within the first few kilobases (,5 kb) from the start of RNA polymerase II transcripts. A non-splicing role for a snRNP has been previously shown for U2 snRNP in the 39-end formation of histone mRNAs 27, 28 .
The mechanism by which U1 snRNP suppresses PCPA is not presently known. However, as it occurs from canonical PASs, it is reminiscent of previous observations on the capacity of tethered U1 snRNP to regulate normal 39-end cleavage and polyadenylation from the natural PASs in the last exon 29 , and may have features in common with it. For example, the U1 snRNP protein U1-70K can interact directly with the poly(A) polymerase (PAP) 30, 31 and inhibit polyadenylation. Targeting 59-mutated U1 snRNAs with complementarity to sequences in the vicinity (within ,500 nucleotides) of the natural PAS at the 39-terminal exon results in degradation of the transcript because cleavage occurs without addition of a poly(A) tail, leaving the transcript vulnerable to 39 exonucleases 32 . A considerable number of genes that we surveyed, but that were not included in our analysis, showed a decrease in exon signals or in both introns and exons throughout the transcript in U1-AMO-treated cells. It is possible that in these cases cleavage occurred without subsequent polyadenylation, and the transcript was therefore rapidly degraded. Alternatively, cleavage and polyadenylation may have occurred very close to the transcription start site, making these transcripts difficult to detect. These scenarios are nevertheless consistent with a role for U1 snRNP in suppressing cleavage and polyadenylation throughout the entire pre-mRNA by a similar machinery that until now was thought to only process the 39 end of mRNA, in an even larger number of genes than our data set presents.
Stochastically, canonical PASs (most frequently AAUAAA or AUUAAA) occur every 2,000 nucleotides, although in several of the genes we studied, including NR3C1, STK17A and BASP1, cryptic PASs are found every 500-800 nucleotides. The strong 59 bias with which PCPA occurred in these genes upon U1 snRNP functional knockdown indicates that one of the first few cryptic PASs is used. Up to the point at which PCPA occurred, these transcripts also contained many cryptic 59 splice sites ( Supplementary Fig. 2) . We propose the following model to explain our observations. Pre-mRNA processing factors, including splicing factors, hnRNP proteins, snRNPs and 39-end cleavage and polyadenylation factors co-transcriptionally associate with nascent transcripts [33] [34] [35] [36] [37] . Direct association of cleavage/polyadenylation factors with the C-terminal domain of RNA polymerase II in the transcription elongation complex has been demonstrated 36 . U1 snRNP associates with nascent transcripts, by base pairing with cognate sequences on the nascent pre-mRNA, including 59 splice sites and cryptic 59 splice sites, and inhibits the cleavage/polyadenylation machinery from attacking the pre-mRNA at cryptic PASs. We envisage that when U1 snRNP's base pairing is prevented, as is the case in U1-AMOtransfected cells, cleavage and polyadenylation occur co-transcriptionally at the first actionable PAS that the transcription elongation complex encounters. By actionable PAS, we mean one that has the necessary hexanucleotide consensus and is in an RNP context that makes it accessible and susceptible to attack by the cleavage/polyadenylation machinery unless U1 snRNP base-paired in the vicinity is able to protect it. We suggest that under normal circumstances, this encounter happens after the last strong U1 binding site (59 splice site or a cryptic 59 splice site) in the 39 untranslated region of the terminal exon because a sufficient density of U1 snRNP base paired throughout protects the transcript up to that point. The likelihood of normal or premature termination may be enhanced by the presence of pausing sites 38 .
U1 snRNP bound to 59 splice sites may thus serve a dual purposein splicing and suppression of PCPA. The perimeter of U1 snRNP's protective zone is not known, but its binding to 59 splice site alone is unlikely to be able to protect the majority of introns, which in humans average ,3.4 kb in length 39 . Furthermore, if suppression of actionable PASs was provided only via U1 snRNP bound to 59 splice sites, 59 splice-site mutations would be expected to cause premature termination, as opposed, for example, to exon skipping, which would be extremely deleterious and, to our knowledge, has not been observed. Additional U1 snRNP binding sites, including cryptic 59 splice sites, may function as tethering sites for its activity in suppression of cleavage and polyadenylation in introns. Viewed from this perspective, sequences referred to as cryptic 59 splice sites may serve a non-splicing purpose to recruit U1 snRNP to protect introns. It is also reasonable to . b, 39 RACE was carried out as described in Fig. 4a using RNA samples from HeLa cells transfected with control or U1 AMOs (7.5 mM) with or without SSA (100 ng ml 21 ) for 8 h. c, HeLa cells were transfected with wild-type and 59 splice site mutant NR3C1 (mutated from AAGGTAAGA to GTCCATTCA) mini-gene. 39 RACE was performed as described in Fig. 4a . The mini-gene structure is depicted. Blue arrow, forward primer to detect PCPA; black arrow, forward primer to detect polyadenylation at 39 end; grey arrowhead, 59 splice site mutation; green and yellow arrowheads, polyadenylation signals in intron and at 39 end, respectively. An unspliced and normally cleaved product was too large to detect. d, Quantification of PCPA and normal polyadenylation at the 39 end represented as fold change in control, which was set to one, and U1-AMO-treated cells was performed using real-time PCR. Error bars indicate s.d. (n 5 3).
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consider that modulating U1 snRNP levels or its binding at sites that protect actionable PASs could be a mechanism for regulating gene expression, including downregulation of the mRNA or switching expression to a different mRNA produced from a prematurely terminated pre-mRNA. We suggest that the vulnerability to PCPA would be expected to increase with increasing intron size if U1 snRNP and cognate base-pairing sites are not available to protect it. We propose that the large excess of U1 snRNP over what is required for splicing in human cells serves an additional critical biological function, to suppress PCPA in introns and protect the integrity of the transcriptome.
METHODS SUMMARY
Antisense morpholino oligonucleotide (AMO) transfection was performed by electroporation. The sequences of the U1 and control AMOs (Gene Tools) are 59-GGTATCTCCCCTGCCAGGTAAGTAT-39 and 59-CCTCTTACCTCAGTT ACAATTTATA-39, respectively 23, 24 . RNase H protection assay was carried out using AMO-transfected cell extracts and antisense DNA oligonucleotide for U1 snRNA (59-CAGGTAAGTAT-39). After RNase H treatment, RNA samples were purified and analysed by northern blotting with a U1 snRNA probe (59-CA AATTATGCAGTCGAGTTTCCCACATTTG-39). In situ hybridization of U1 snRNA was performed with a biotin-labelled LNA probe (59-GGTATCTC CCCTGCCAGGTAAGTAT-39). Nuclei were stained by DAPI. For in vitro splicing, [a-32 P]UTP labelled Ad2DIVS pre-mRNA was prepared as previously described 40 . In vitro splicing reactions were carried out in 293T whole cell extracts prepared as previously described 41 . Splicing products were resolved on denaturing PAGE, and gels were autoradiographed. For tiling array, labelled cDNA targets were prepared and applied to Affymetrix GeneChip human tiling 2.0R E arrays. Arrays were scanned to produce .CEL files. The .CEL files were analysed using the Affymetrix Tiling Analysis Software (TAS) to produce .BED files of signal intensity and P-value. Overlapping regions of two data sets were chosen using Galaxy (http://galaxy.psu.edu/) 42 . We produced .BAR files from the .CEL files using TAS to visualize on the Integrated Genome Browser (Affymetrix). For 39 RACE, cDNA was synthesized from total RNA using an oligo dT18-XbaKpnBam primer. The first and second (nested) PCR reactions were performed using gene-specific forward primers and the XbaKpnBam reverse primer. For 39 RACE of the NR3C1 mini-gene, pcDNA3.1-59 primer was used as the first primer to distinguish mini-gene RNA from endogenous NR3C1 RNA. To construct the NR3C1 mini-gene, DNA fragments of NR3C1 intron 1-exon 2-intron 2 and NR3C1 intron 2-exon 3 were amplified and subcloned into pcDNA3.1 vector. The poly(A) site and 59 splice site were mutated in this construct where indicated. Sequences of all primers are listed in Supplementary Table 1 .
